Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2022 ∙ ACIP

Updates from the Pneumococcal Vaccines Work Group

  • Background paper
  • Americas
  • United States of America
  • Pneumococcal disease
Download:
2021 ∙ Wang, B. C. Chaiyakunapruk, N. Zhu, S. Babigumira, J. B. Furnback, W. Chitale, R. Gamil, A. Zhao, K. Wasserman, M.

A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)

  • Western Pacific
  • Children
  • Newborn
  • Pneumococcal disease
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2021 ∙ Shao, Y. Stoecker, C.

Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review

  • Adults
  • Older adults
  • Low and Middle Income Countries
  • Pneumococcal disease
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2021 ∙ Ishiwada, N.

Current situation and need for prevention of invasive pneumococcal disease and pneumococcal pneumonia in 6- to 64-year-olds in Japan

  • Western Pacific
  • Japan
  • All age groups
  • Pneumococcal disease
  • Coverage
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2021 ∙ Rosamilia, F. Noberasco, G. Olobardi, D. Orsi, A. Icardi, G. Lantieri, F. Murdaca, G.

Flu and pneumococcal vaccine coverage in scleroderma patients still need to be prompted: A systematic review

  • All age groups
  • Influenza
  • Pneumococcal disease
  • Coverage
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2021 ∙ Wang, L. M. Hashiguchi, T. C. O. Cecchini, M.

Impact of vaccination on carriage of and infection by antibiotic-resistant bacteria: A systematic review and meta-analysis

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2021 ∙ Marques Antunes, M. Duarte, G. S. Brito, D. Borges, M. Costa, J. Ferreira, J. J. Pinto, F. J. Caldeira, D.

Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis

  • Adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2021 ∙ Zhu, X. Li, X.

Pneumococcal vaccine effect on hospitalisation rates of pneumonia in children: A meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2021 ∙ Desalermos, A. Pimienta, M. Kalligeros, M. Shehadeh, F. Diamantopoulos, L. Karamanolis, G. Caldera, F. Farraye, F. A.

Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis

  • Adults
  • Hepatitis B
  • Influenza
  • Herpes zoster
  • Pneumococcal disease
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2021 ∙ Bhanu, C. Gopal, D. P. Walters, K. Chaudhry, U. A. R.

Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review

  • Adults
  • Older adults
  • Influenza
  • Pneumococcal disease
  • Diphtheria
  • Pertussis
  • Tetanus
  • Ethical issues
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
Loading...